

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲頂新耀有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

**VOLUNTARY ANNOUNCEMENT
INCREASE IN SHAREHOLDING BY
SUBSTANTIAL SHAREHOLDER OF THE COMPANY**

This announcement is made by Everest Medicines Limited (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company was informed by Mr. Wei Fu (“**Mr. Fu**”), a non-executive Director, the honorary chairman of the Board and a substantial shareholder of the Company, that from 8 June 2026 to 9 June 2026, CBC Group (being a substantial shareholder of the Company) purchased 679,000 ordinary shares of the Company (the “**Shares**”) on the market for a total consideration of approximately HK\$18.9 million, representing an average price of approximately HK\$27.90 per Share.

As advised by Mr. Fu and CBC Group, the purchases through on-market acquisitions of Shares were made based on his strong confidence in the future prospects and long-term development of the Company. Mr. Fu and CBC Group does not rule out the possibility of further increasing his shareholdings in the Company as and when appropriate subject to compliance with the applicable laws and regulations.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 10 June 2026

As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. William Ki Chul Cho and Mr. Xin Sun as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.